Dave Laffan

David Laffan has over 30 years’ experience in the chemical and pharmaceutical industry, starting with Lonza for 6 years and then at AstraZeneca, where he is currently a Senior Director in Chemical Development. His background has been in small molecules and his group have been responsible for the Drug Substance development and commercialisation of several successful medicines including Crestor in 2002 through to more recently Calquence in 2017 and Koselugo in 2020. His group still includes traditional small molecules but has additionally taken on responsibility for the drug substance development of AZ’s peptides, oligonucleotides and other new modalities. These should be coming to commercialisation in the next few years so he has taken a particular interest in the future large scale supply of these modalities.